MetaCap

BillionToOne Inc. Class A (BLLN)

NASDAQ: BLLNHealth CareMedical SpecialitiesUSD

89.92-0.28 (-0.31%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BLLN stock chart

Technical analysis

Key statistics

All statistics
52-week range
61.96 – 150.44
Day range
88.00 – 91.43
Volume / Avg
819.34K / 639.36K
Beta
—

52-week range

$61.96$150.44

BLLN stock today

Shares of BillionToOne (BLLN) finished lower on Nov 20 at $89.92, a drop of 0.31% or $0.28 per share, versus the S&P 500's 3.70% decline. At this level, BLLN sits in the middle of its 52-week range of $61.96 to $150.44: 40.2% below the high, set on Aug 5, 2026 and 45.1% above the low. BLLN is up 9.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 18.3%.

At 97.7x trailing earnings, BillionToOne trades above the peer-group median of 20.5x. Its forward P/E of 57.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About BillionToOne

Company profile

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision.

Industry
Medical Specialities
CEO
Dr. Oguzhan Atay Ph.D.
Headquarters
Menlo Park, CA
Employees
713
IPO year
2025

Financial highlights

Full financials

In fiscal 2025, BillionToOne generated $305.1 million in revenue, up 100.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $7.5 million, for a net margin of 2.4% versus a median of -71.3% in the prior 2 years. Gross margin was 68.3% (up from 53.0%) and operating margin 5.3%.

BillionToOne annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$305.11M$152.58M$71.73M
Growth+99.97%+112.72%—
Net income$7.45M$-41.57M$-82.68M
EPS (diluted)$0.14$-4.12$-8.45

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$128.29+42.67%

  • Strong buy 2
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $110.00High $145.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.32 vs $0.16
Surprise
+100.00%

BLLN news

All BLLN news

BillionToOne peers

Health Care sector
BLLN peer companies
CompanyPrice% ChgMarket capCompare
GRALGRAIL Inc.99.25-5.33%$4.46Bvs BLLN
CDNACareDx Inc.70.00-2.67%$3.68Bvs BLLN
CAICaris Life Sciences Inc.17.58-5.18%$5.04Bvs BLLN
CONConcentra Group Holdings Parent Inc.41.84+0.94%$5.26Bvs BLLN
ACHCAcadia Healthcare Company Inc.34.60+0.38%$3.22Bvs BLLN
RDNTRadNet Inc.69.71+0.29%$5.49Bvs BLLN
CELCCelcuity Inc.53.35-5.26%$2.61Bvs BLLN
VCYTVeracyte Inc.25.13+0.36%$2.03Bvs BLLN

Indexes, lists and sector

BillionToOne stock FAQ

What is BillionToOne's stock price today?

BLLN last traded at $89.92 as of Nov 20, 4:00 PM EST, down 0.31% on the day. Prices are delayed at least 15 minutes.

What is BLLN's P/E ratio?

BLLN trades at a trailing P/E ratio of 97.74 and a forward P/E of 57.27, compared with a median of 20.5 for its closest peers.

Who is BillionToOne's CEO?

Dr. Oguzhan Atay Ph.D. is the chief executive officer of BillionToOne Inc. Class A, which has about 713 employees.

What is the BLLN 52-week high?

The 52-week high for BLLN is $150.44 and the 52-week low is $61.96. The stock is currently 40.2% below its high.

Compare BLLN